TNF Inhibitor denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for TNF Inhibitors

TNF inhibitors are high-cost biologic agents, and UHC universally requires prior authorization (PA) before it will cover them. A "prior auth required" denial means the claim was submitted without an approved PA on file — either no PA was requested, the PA was pending when the prescription was filled, or the PA was approved under different parameters (different drug, indication, or quantity) than what was dispensed.

This is a procedural denial, not a clinical one, but it still requires action to get the medication covered going forward.

## Why This Denial Is Appealable

If the PA process was not completed due to a plan administrative error, a prescriber office delay, or a failure to notify you of the PA requirement, that context supports an appeal. Additionally, if you have already been taking the TNF inhibitor and are seeking retroactive coverage, an appeal on clinical-necessity grounds can be successful when the documentation clearly supports the use. ACA §2719 and ERISA §503 provide full internal and external review rights.

## Federal Appeal Framework

• Concurrent path — new PA request: While appealing the denial, the prescriber's office should simultaneously submit a complete PA request with all supporting clinical documentation so future fills are not interrupted.
• Internal appeal: File within 180 days for retroactive coverage consideration.
• External review: Available after the internal process is exhausted; the IRO reviews whether the coverage denial was appropriate.
• Expedited review: Request immediately if you are mid-therapy and a gap in treatment would harm your health.

## Documentation to Gather

1. PA submission records — evidence that a PA was submitted (or attempted) with the date and any reference numbers; if the prescriber submitted it, obtain their confirmation. 2. Diagnosis and clinical summary — specialist notes confirming the indication, disease severity, and treatment history. 3. Prior-therapy documentation — records of previous conventional therapies tried, with dates and outcomes, demonstrating that PA-required step-therapy requirements were met. 4. Prescriber letter — a medical-necessity letter from the treating physician addressing each criterion in UHC's PA requirements for TNF inhibitors. 5. Continuity-of-care argument (if already on therapy) — documentation of ongoing response and clinical stability on the TNF inhibitor, supporting retroactive and continued coverage.

## Criteria-Mapping Structure

Obtain UHC's current PA criteria for the specific TNF inhibitor and map each requirement:

| PA Criterion (from UHC policy) | Supporting Record | |---|---| | Confirmed covered indication | Specialist diagnosis note, date ___ | | Required prior therapies completed | Pharmacy and chart records, dates ___ | | Prescribing by or in consultation with specialist | Physician credentials on file | | Absence of covered preferred alternative | Prescriber explanation if applicable |

Review the FDA-approved labeling for the prescribed TNF inhibitor and UHC's current PA criteria carefully before submitting — the exact requirements must come from those primary sources, as they are updated periodically.